story of the week
Neoadjuvant Talimogene Laherparepvec Plus Surgery for Resectable Stage IIIB–IVM1a Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial
Nat. Med. 2021 Oct 01;27(10)1789-1796, R Dummer, DE Gyorki, J Hyngstrom, AC Berger, R Conry, L Demidov, A Sharma, SA Treichel, H Radcliffe, KS Gorski, A Anderson, E Chan, M Faries, MI RossFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.